Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001666071-20-000035)

Filing Details

Accession Number:
0001666071-20-000035
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-26 06:11:17
Reporting Period:
2020-02-24
Accepted Time:
2020-02-26 06:11:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1666071 Cardlytics Inc. CDLX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1617486 D. Scott Grimes C/O Cardlytics, Inc.
675 Ponce De Leon Avenue Ne, Suite 6000
Atlanta GA 30308		 Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-02-24 1,000 $90.00 139,112 No 4 S Indirect See Footnote
Common Stock Disposition 2020-02-25 800 $83.44 386,403 No 4 S Direct
Common Stock Disposition 2020-02-25 3,116 $84.60 383,287 No 4 S Direct
Common Stock Disposition 2020-02-25 581 $85.47 382,706 No 4 S Direct
Common Stock Disposition 2020-02-25 200 $87.13 382,506 No 4 S Direct
Common Stock Disposition 2020-02-25 2,803 $88.49 379,703 No 4 S Direct
Common Stock Disposition 2020-02-25 2,000 $89.23 377,703 No 4 S Direct
Common Stock Disposition 2020-02-25 200 $90.17 377,503 No 4 S Direct
Common Stock Disposition 2020-02-25 100 $91.36 377,403 No 4 S Direct
Common Stock Disposition 2020-02-25 200 $92.56 377,203 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019.
  2. The reportable securities are held by the GRAT.
  3. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018, as amended May 14, 2019.
  4. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $83.12 to $83.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4), (5), (6), (7), (8), (9), (10), (11) and (12) to this Form 4.
  5. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $84.14 to $84.93, inclusive.
  6. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $85.19 to $85.69, inclusive.
  7. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $86.75 to $87.505, inclusive.
  8. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $87.83 to $88.80, inclusive.
  9. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $88.88 to $89.86, inclusive.
  10. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $89.96 to $90.37, inclusive.
  11. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $91.36 to $91.47, inclusive.
  12. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $92.40 to $92.71, inclusive.